Hetero's COVID-19 oral drug gets WHO prequalification

WHO made a strong recommendation for nirmatrelvir and ritonavir for mild and moderate COVID-19 patients at highest risk of hospital admission

Center advises states to be on alert and keep all preparedness for COVID-19 management: Dr. Mandaviya

Centre and states need to work in tandem and in a collaborative spirit as was done during the previous surges for COVID-19 prevention and management

PM emphasises need for strengthened surveillance with focus on genome sequencing and increased testing

Modi stressed the need to ensure that the entire Covid infrastructure at all levels is maintained at a high level of preparedness in terms of equipment, processes, and human resources

Ezharima launched in Japan as first dual EZH1 and EZH2 inhibitor therapy for leukemiaLymphoma

EZHARMIA is the fifth innovative oncology medicine to be launched in Japan by Daiichi Sankyo in the past three years

Enhertu to demonstrate a significant survival benefit vs. chemotherapy

Guerison to set up footprints in India’s ophthalmology market

Global pharmaceutical company having a surgical business concept incepted in Dubai

Imfinzi plus Imjudo recommended for approval in the EU by CHMP for advanced liver and lung cancers

Positive opinions based on significant survival benefit

Mandaviya inaugurates ICMR-NARFBR in Hyderabad

The newly built centre will work as the state-of-the-art facility for not just ethical animal studies but spans from basic, applied to regulatory animal research.

Takeda launches CINRYZE in India for hereditary angioedema patients

CINRYZE is plasma-derived C1-I NH approved for routine prevention (prophylaxis), short-term prevention or pre-procedure prevention, and acute attacks of HAE.

Biocon initiates clinical study of Itolizumab for ulcerative colitis in India

This is a phase two randomized, double-blind, parallel-group, placebo and active-controlled study